Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinberg, Frank, Gadgeel, Shirish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556538/
https://www.ncbi.nlm.nih.gov/pubmed/31239797
http://dx.doi.org/10.2147/LCTT.S176391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556538/
https://www.ncbi.nlm.nih.gov/pubmed/31239797
http://dx.doi.org/10.2147/LCTT.S176391

Ejemplares similares